Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation

Shosaku Nomura, Yoshinobu Maeda, Kazuyoshi Ishii, Yuta Katayama, Hideo Yagi, Naoto Fujishima, Shuichi Ota, Masato Moriyama, Takayuki Ikezoe, Yasuhiko Miyazaki, Kunio Hayashi, Shinya Fujita, Atsushi Satake, Tomoki Ito, Taiichi Kyo, Mitsune Tanimoto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Conditioning regimens including total body irradiation (TBI) or cyclophosphamide can mobilize high-mobility group box 1 (HMGB1) to peripheral blood. Additionally, increased plasminogen activator inhibitor (PAI)-1 levels are associated with post-allogeneic hematopoietic stem cell transplantation (aHSCT). However, changes to circulating levels of HMGB1 after aHSCT are poorly understood. Materials and methods: The study cohort included 289 patients who underwent aHSCT at one of 25 institutions in Japan. We have investigated the relationship between HMGB1 and PAI-1 following aHSCT. A significant increase in HMGB1 levels occurred after conditioning treatment. Additionally, levels of HMGB1 at day 0 were significantly increased in TBI+ patients and cyclophosphamide/TBI patients. Conclusion: Our data revealed that an increased level of HMGB1 at day 0 following aHSCT correlates with increased PAI-1 after aHSCT, which is consistent with previous reports. Increased HMGB1 at day 0 after a conditioning regimen may play a role in transplantation-associated coagulopathy following aHSCT, because PAI-1 can accelerate procoagulant activity.

Original languageEnglish
JournalJournal of Blood Medicine
Volume7
DOIs
Publication statusPublished - Jan 18 2016

Fingerprint

Hematopoietic Stem Cell Transplantation
Plasminogen Activator Inhibitor 1
Whole-Body Irradiation
Cyclophosphamide
Japan
Cohort Studies
Transplantation

Keywords

  • AHSCT
  • HMGB1
  • PAI-1
  • TBI
  • Transplantation-associated coagulopathy

ASJC Scopus subject areas

  • Hematology

Cite this

Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation. / Nomura, Shosaku; Maeda, Yoshinobu; Ishii, Kazuyoshi; Katayama, Yuta; Yagi, Hideo; Fujishima, Naoto; Ota, Shuichi; Moriyama, Masato; Ikezoe, Takayuki; Miyazaki, Yasuhiko; Hayashi, Kunio; Fujita, Shinya; Satake, Atsushi; Ito, Tomoki; Kyo, Taiichi; Tanimoto, Mitsune.

In: Journal of Blood Medicine, Vol. 7, 18.01.2016.

Research output: Contribution to journalArticle

Nomura, S, Maeda, Y, Ishii, K, Katayama, Y, Yagi, H, Fujishima, N, Ota, S, Moriyama, M, Ikezoe, T, Miyazaki, Y, Hayashi, K, Fujita, S, Satake, A, Ito, T, Kyo, T & Tanimoto, M 2016, 'Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation', Journal of Blood Medicine, vol. 7. https://doi.org/10.2147/JBM.S93008
Nomura, Shosaku ; Maeda, Yoshinobu ; Ishii, Kazuyoshi ; Katayama, Yuta ; Yagi, Hideo ; Fujishima, Naoto ; Ota, Shuichi ; Moriyama, Masato ; Ikezoe, Takayuki ; Miyazaki, Yasuhiko ; Hayashi, Kunio ; Fujita, Shinya ; Satake, Atsushi ; Ito, Tomoki ; Kyo, Taiichi ; Tanimoto, Mitsune. / Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation. In: Journal of Blood Medicine. 2016 ; Vol. 7.
@article{56128ec046c1495b8bb6f2b1e9570f98,
title = "Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation",
abstract = "Background: Conditioning regimens including total body irradiation (TBI) or cyclophosphamide can mobilize high-mobility group box 1 (HMGB1) to peripheral blood. Additionally, increased plasminogen activator inhibitor (PAI)-1 levels are associated with post-allogeneic hematopoietic stem cell transplantation (aHSCT). However, changes to circulating levels of HMGB1 after aHSCT are poorly understood. Materials and methods: The study cohort included 289 patients who underwent aHSCT at one of 25 institutions in Japan. We have investigated the relationship between HMGB1 and PAI-1 following aHSCT. A significant increase in HMGB1 levels occurred after conditioning treatment. Additionally, levels of HMGB1 at day 0 were significantly increased in TBI+ patients and cyclophosphamide/TBI patients. Conclusion: Our data revealed that an increased level of HMGB1 at day 0 following aHSCT correlates with increased PAI-1 after aHSCT, which is consistent with previous reports. Increased HMGB1 at day 0 after a conditioning regimen may play a role in transplantation-associated coagulopathy following aHSCT, because PAI-1 can accelerate procoagulant activity.",
keywords = "AHSCT, HMGB1, PAI-1, TBI, Transplantation-associated coagulopathy",
author = "Shosaku Nomura and Yoshinobu Maeda and Kazuyoshi Ishii and Yuta Katayama and Hideo Yagi and Naoto Fujishima and Shuichi Ota and Masato Moriyama and Takayuki Ikezoe and Yasuhiko Miyazaki and Kunio Hayashi and Shinya Fujita and Atsushi Satake and Tomoki Ito and Taiichi Kyo and Mitsune Tanimoto",
year = "2016",
month = "1",
day = "18",
doi = "10.2147/JBM.S93008",
language = "English",
volume = "7",
journal = "Journal of Blood Medicine",
issn = "1179-2736",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation

AU - Nomura, Shosaku

AU - Maeda, Yoshinobu

AU - Ishii, Kazuyoshi

AU - Katayama, Yuta

AU - Yagi, Hideo

AU - Fujishima, Naoto

AU - Ota, Shuichi

AU - Moriyama, Masato

AU - Ikezoe, Takayuki

AU - Miyazaki, Yasuhiko

AU - Hayashi, Kunio

AU - Fujita, Shinya

AU - Satake, Atsushi

AU - Ito, Tomoki

AU - Kyo, Taiichi

AU - Tanimoto, Mitsune

PY - 2016/1/18

Y1 - 2016/1/18

N2 - Background: Conditioning regimens including total body irradiation (TBI) or cyclophosphamide can mobilize high-mobility group box 1 (HMGB1) to peripheral blood. Additionally, increased plasminogen activator inhibitor (PAI)-1 levels are associated with post-allogeneic hematopoietic stem cell transplantation (aHSCT). However, changes to circulating levels of HMGB1 after aHSCT are poorly understood. Materials and methods: The study cohort included 289 patients who underwent aHSCT at one of 25 institutions in Japan. We have investigated the relationship between HMGB1 and PAI-1 following aHSCT. A significant increase in HMGB1 levels occurred after conditioning treatment. Additionally, levels of HMGB1 at day 0 were significantly increased in TBI+ patients and cyclophosphamide/TBI patients. Conclusion: Our data revealed that an increased level of HMGB1 at day 0 following aHSCT correlates with increased PAI-1 after aHSCT, which is consistent with previous reports. Increased HMGB1 at day 0 after a conditioning regimen may play a role in transplantation-associated coagulopathy following aHSCT, because PAI-1 can accelerate procoagulant activity.

AB - Background: Conditioning regimens including total body irradiation (TBI) or cyclophosphamide can mobilize high-mobility group box 1 (HMGB1) to peripheral blood. Additionally, increased plasminogen activator inhibitor (PAI)-1 levels are associated with post-allogeneic hematopoietic stem cell transplantation (aHSCT). However, changes to circulating levels of HMGB1 after aHSCT are poorly understood. Materials and methods: The study cohort included 289 patients who underwent aHSCT at one of 25 institutions in Japan. We have investigated the relationship between HMGB1 and PAI-1 following aHSCT. A significant increase in HMGB1 levels occurred after conditioning treatment. Additionally, levels of HMGB1 at day 0 were significantly increased in TBI+ patients and cyclophosphamide/TBI patients. Conclusion: Our data revealed that an increased level of HMGB1 at day 0 following aHSCT correlates with increased PAI-1 after aHSCT, which is consistent with previous reports. Increased HMGB1 at day 0 after a conditioning regimen may play a role in transplantation-associated coagulopathy following aHSCT, because PAI-1 can accelerate procoagulant activity.

KW - AHSCT

KW - HMGB1

KW - PAI-1

KW - TBI

KW - Transplantation-associated coagulopathy

UR - http://www.scopus.com/inward/record.url?scp=84977913832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977913832&partnerID=8YFLogxK

U2 - 10.2147/JBM.S93008

DO - 10.2147/JBM.S93008

M3 - Article

VL - 7

JO - Journal of Blood Medicine

JF - Journal of Blood Medicine

SN - 1179-2736

ER -